RecruitingPhase 2NCT07277660

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Moderate to Severe Atopic Dermatitis

Sponsor

UCB Biopharma SRL

Enrollment

160 participants

Start Date

Dec 29, 2025

Study Type

INTERVENTIONAL

Conditions

Atopic Dermatitis

Summary

The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Galvokimig and a drug called Placebo for people with atopic dermatitis. The study is currently recruiting participants at 64 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALGalvokimig

Drug: Galvokimig Pharmaceutical form: Solution for injection

DRUGPlacebo

Drug: Placebo Pharmaceutical form: Solution for injection

Locations(68)

Atd002 52021

Oceanside, California, United States

Atd002 52008

Santa Monica, California, United States

Atd002 52013

Boca Raton, Florida, United States

Atd002 52007

Miami, Florida, United States

Atd002 52003

Miami, Florida, United States

Atd002 52015

Savannah, Georgia, United States

Atd002 52017

Chicago, Illinois, United States

Atd002 52018

Wheaton, Illinois, United States

Atd002 52012

New Albany, Indiana, United States

Atd002 52014

Bowling Green, Kentucky, United States

Atd002 52001

Troy, Michigan, United States

Atd002 52009

Troy, Michigan, United States

Atd002 52010

Omaha, Nebraska, United States

Atd002 52022

New York, New York, United States

Atd002 52020

The Bronx, New York, United States

Atd002 52019

Philadelphia, Pennsylvania, United States

Atd002 52005

Dallas, Texas, United States

Atd002 52016

Frisco, Texas, United States

Atd002 52011

Frisco, Texas, United States

Atd002 52004

Sugar Land, Texas, United States

Atd002 41004

Lovech, Bulgaria

Atd002 41001

Pleven, Bulgaria

Atd002 41007

Plovdiv, Bulgaria

Atd002 41002

Sevlievo, Bulgaria

Atd002 41003

Sofia, Bulgaria

Atd002 41005

Sofia, Bulgaria

Atd002 41006

Sofia, Bulgaria

Atd002 51002

Edmonton, Canada

Atd002 51006

Hamilton, Canada

Atd002 51007

Toronto, Canada

Atd002 51003

Vancouver, Canada

Atd002 42002

Náchod, Czechia

Atd002 42001

Prague, Czechia

Atd002 42003

Prague, Czechia

Atd002 42004

Prague, Czechia

Atd002 42005

Prague, Czechia

Atd002 43001

Bad Bentheim, Germany

Atd002 43005

Dresden, Germany

Atd002 43002

Frankfurt, Germany

Atd002 43004

Leipzig, Germany

Atd002 43003

Lübeck, Germany

Atd002 43007

Mahlow, Germany

Atd002 44003

Budapest, Hungary

Atd002 44001

Debrecen, Hungary

Atd002 21001

Habikino, Japan

Atd002 21002

Nagasaki, Japan

Atd002 21007

Nagoya, Japan

Atd002 21005

Sakai, Japan

Atd002 21008

Sapporo, Japan

Atd002 21004

Tachikawa-shi, Japan

Atd002 21006

Yokohama, Japan

Atd002 45011

Chorzów, Poland

Atd002 45001

Katowice, Poland

Atd002 45003

Krakow, Poland

Atd002 45007

Krakow, Poland

Atd002 45010

Krakow, Poland

Atd002 45014

Krakow, Poland

Atd002 45004

Lodz, Poland

Atd002 45013

Lodz, Poland

Atd002 45005

Sosnowiec, Poland

Atd002 45009

Tarnów, Poland

Atd002 45002

Warsaw, Poland

Atd002 45006

Warsaw, Poland

Atd002 45008

Wroclaw, Poland

Atd002 46004

London, United Kingdom

Atd002 46007

London, United Kingdom

Atd002 46003

Salford, United Kingdom

Atd002 46006

Sheffield, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07277660

Related Trials

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

NCT072629831 location

Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

NCT068992041 location

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

NCT065643895 locations

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)

NCT0723994710 locations

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

NCT0680728137 locations